Author:
Schlenk Richard F., ,Lübbert Michael,Benner Axel,Lamparter Alexander,Krauter Jürgen,Herr Wolfgang,Martin Hans,Salih Helmut R.,Kündgen Andrea,Horst Heinz-A.,Brossart Peter,Götze Katharina,Nachbaur David,Wattad Mohammed,Köhne Claus-Henning,Fiedler Walter,Bentz Martin,Wulf Gerald,Held Gerhard,Hertenstein Bernd,Salwender Hans,Gaidzik Verena I,Schlegelberger Brigitte,Weber Daniela,Döhner Konstanze,Ganser Arnold,Döhner Hartmut
Funder
German Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft
Deutsche José Carreras Leukämie-Stiftung
Pfizer germany
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference39 articles.
1. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111–21
2. Lo-Coco F, Di Donato L, GIMEMA, Schlenk RF, German–Austrian Acute Myeloid Leukemia Study Group and Study Alliance Leukemia (2016) Targeted therapy alone for acute promyelocytic leukemia. N Engl J Med 374(12):1197–8
3. Hu ZB, Minden MD, McCulloch EA (1995) Direct evidence for the participation of bcl-2 in the regulation by retinoic acid of the Ara-C sensitivity of leukemic stem cells. Leukemia 9:1667–73
4. Yang GS, Minden MD, McCulloch EA (1993) Influence of schedule on regulated sensitivity of AML blasts to cytosine arabinoside. Leukemia 7:1012–9
5. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE et al (1999) Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 13:1881–92